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Eastern Virginia Medical School, Norfolk, VA, United States, 2 Department of Human Movement Sciences, Old Dominion
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Autonomic nervous system (ANS) imbalance manifesting as cardiac autonomic
neuropathy in the diabetic population is an important predictor of cardiovascular
events. Symptoms and signs of ANS dysfunction, such as resting heart rate elevations,
diminished blood pressure responses to standing, and altered time and frequency
domain measures of heart rate variability in response to deep breathing, standing,
and the Valsalva maneuver, should be elicited from all patients with diabetes and
prediabetes. With the recognition of the presence of ANS imbalance or for its prevention,
a rigorous regime should be implemented with lifestyle modification, physical activity,
and cautious use of medications that lower blood glucose. Rather than intensifying
diabetes control, a regimen tailored to the individual risk of autonomic imbalance
should be implemented. New agents that may improve autonomic function, such as
SGLT2 inhibitors, should be considered and the use of incretins monitored. One of the
central mechanisms of dysfunction is disturbance of the hypothalamic cardiac clock,
a consequence of dopamine deficiency that leads to sympathetic dominance, insulin
resistance, and features of the metabolic syndrome. An improvement in ANS balance
may be critical to reducing cardiovascular events, cardiac failure, and early mortality in
the diabetic population.
Keywords: cardiac autonomic neuropathy, sympathetic, parasympathetic, dopamine deficiency, insulin
resistance, cardiovascular event prediction, heart rate variability, diabetes
Abbreviations: ACCORD, action to control cardiovascular risk in diabetes; ACE inhibitors, angiotensin-converting enzyme
inhibitors; AN, autonomic neuropathy; ANS, autonomic nervous system; ARBs, angiotensin receptor blockers; BP, blood
pressure; CAD, coronary artery disease; CAN, cardiac autonomic neuropathy; CARTs, cardiovascular autonomic reflex
tests; COX-2, cyclooxygenase-2; CVD, cardiovascular disease; DCCT, diabetic control and complications trial; DM, diabetes
mellitus; DN, diabetic neuropathy; DPN, diabetic peripheral neuropathy; EDIC, epidemiology of diabetes interventions
and complications; GLP-1, glucagon-like peptide-1; HF, high frequency; HR, heart rate; HRV, heart rate variability; LF, low
frequency; Lfa, low frequency area; MI, myocardial ischemia; Rfa, respiratory frequency area; rMSSD, root-mean-square
of the difference of successive R–R interval; sdNN, standard deviation of all normal R–R intervals; T1DM, type 1 diabetes
mellitus; T2DM, type 2 diabetes mellitus.
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INTRODUCTION
As the United States population grows older and more obese,
fully one third of people over the age of 65 will develop
diabetes (Cowie et al., 2009; Boyle et al., 2010) and a host
of comorbidities; and almost two thirds of these patients
will experience cardiometabolic events. Unfortunately, the
existence of comorbidities like metabolic syndrome, obesity,
hyperlipidemia, and hypertension predict only about 24% of the
risk of such events. Neuropathy (of all types) is one of the most
prevailing complications of diabetes and a considerable source
of morbidity and mortality; it includes DPN and AN (Vinik
et al., 2013). AN, particularly when it involves cardiac function
(CAN), independently predicts risk of cardiovascular death and
myocardial infarction (MI) resulting in substantial morbidity and
mortality (Pop-Busui et al., 2017).
It is likely that dysfunction of the ANS is an underdiagnosed
cause of excessive morbidity and mortality in adults with diabetes.
In fact, CAN results in cardiovascular (CV) dysfunction and is
often accompanied by the progression to myocardial ischemia
(which is often silent in diabetes), stroke, CAD, perioperative
morbidity, and overall morbidity and mortality (Maser et al.,
2003; Vinik and Ziegler, 2007; Pop-Busui et al., 2010). In
combination with signs of DPN, the odds ratio increases to 4.55
for mortality and CVD (Vinik, 2010). This is a more robust
indicator of CVD risk, exceeding lipoprotein profile, BP, as well
as adenosine scans (Vinik et al., 2010). Thus, CAN assessments
may be useful to predict cardiovascular risk.
CARDIAC AUTONOMIC NEUROPATHY
AND RISK OF CARDIOVASCULAR
EVENTS AND MORTALITY
The prevalence of diabetes-related AN may be as high as 90%
depending on the diagnostic methods and the cohort studied
(Ziegler et al., 1992; Vinik et al., 2003). CAN prevalence increases
substantially with diabetes duration in both T1DM (30% after
20 years) (Pop-Busui et al., 2009; Spallone et al., 2011; Martin
et al., 2014) and T2DM (up to 60% after 15 years) (Low,
1996; Low et al., 2004; Spallone et al., 2011). In addition,
CAN is present in some patients with prediabetes (Carnethon
et al., 2006; Ziegler et al., 2008a, 2015b). CAN is strongly
associated with risk of arrhythmias, major cardiovascular events,
myocardial dysfunction, and cardiovascular mortality (Maser
et al., 2003; Lykke et al., 2008; Ziegler et al., 2008b; Young
et al., 2009; Pop-Busui et al., 2010, 2013). Consequently,
early diagnosis of cardiac autonomic dysfunction is important.
Several studies including ADVANCE, VADT, and ACCORD
(Wackers et al., 2004; The Advance Collaborative Group, 2008;
Duckworth et al., 2009; Pop-Busui, 2010; Pop-Busui et al.,
2010; Zoungas et al., 2017) have shown that cardiac autonomic
dysfunction may predict the risk of cardiovascular events and
sudden death seen with intensification of glycemic control in
subjects with T2DM. Significant escalations in cardiovascular
events and all causes of mortality were independently correlated
with resting baseline and average HR in a post hoc analysis
of the ONTARGET/TRANSCEND studies, two large cohort
studies of patients with stable, chronic CVD (Lonn et al.,
2014). The influence of elevated resting HR and blunted
HRV, two measures of ANS imbalance, on the development
and progression of CVD, diabetes, and early mortality was
assessed by Wulsin et al. (2015). In this Framingham Heart
Study offspring cohort these measures, in addition to smoking,
age, and gender, were shown to be significant predictors for
developing CVD, DM, and early mortality within 12 years.
Zafrir et al. (2016) also showed that resting tachycardia
(HR > 100 beats/minute), chronotropic incompetence (inability
of the heart to increase its rate commensurate with increased
activity or demand), and reduced HR recovery after treadmill
exercise were independently correlated with stroke, MI, and
overall mortality in T2DM patients (hazard ratios of 1.97,
1.89, and 1.77, respectively), regardless of established coronary
heart disease. In addition, the EURODIAB Prospective Cohort
Study (Soedamah-Muthu et al., 2008) revealed that CAN was
the most distinctive predictor for mortality in a large group
of patients with T1DM, and increased mortality risk with
deteriorating CAN was shown in a meta-analysis of several trials
(Maser et al., 2003).
DETECTION OF CARDIAC AUTONOMIC
NEUROPATHY
The most frequent clinical symptoms of CAN include dizziness,
heart palpitations, lightheadedness, and fragility, all of which
are consequences of dysregulation of the cardiovascular
system secondary to malfunction of the sympathetic and
parasympathetic nervous systems. Early autonomic dysfunction
may exhibit no symptoms and only be detected by abnormal
indices of HRV. Resting tachycardia (>100 bpm) and/or a
fixed HR, as well as, orthostatic hypotension, intolerance to
exercise, and syncope are present in patients with advanced
CAN (The Consensus Committee of the American Autonomic
Society and the American Academy of Neurology, 1996; Vinik
and Ziegler, 2007; Pop-Busui, 2010; Spallone et al., 2011). In
advanced stages diagnosis can be done clinically, but HRV
tests may be necessary to detect early asymptomatic cardiac
autonomic dysfunction. This can be easily performed in the
office by utilizing an electrocardiogram recording during either
1–2 min of deep breathing, or as the subject begins to rise from
a seated position, with calculation of HRV indices (Pop-Busui
et al., 2017) (Table 1).
ADA recommendations regarding screening and diagnosis of
CAN are as follows (Pop-Busui et al., 2017):
• “Symptoms and signs of AN should be assessed in patients
with microvascular and neuropathic complications.
• In the presence of symptoms or signs of cardiovascular
AN, tests excluding other comorbidities or drug
effects/interactions that could mimic cardiovascular
AN should be performed.
• Consider assessing symptoms and signs of cardiovascular
AN in patients with hypoglycemia unawareness.”
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TABLE 1 | Diagnostic tests for cardiovascular autonomic neuropathy (adapted from Brownlee et al., 2016).
Resting heart rate
Rate > 100 beats/min is abnormal
Beat-to-beat heart rate variation∗
With the patient at rest and supine (no overnight coffee or hypoglycemic episodes), breathing 6 breaths/min, heart rate monitored by ECG, an HRV of > 15 beats/min is
normal and < 10 beats/min is abnormal, E/I ratio of R–R intervals > 1.17. All indices of HRV are age-dependent.†
Heart rate response to standing∗
During continuous ECG monitoring, the R–R interval is measured at beats 15 and 30 after standing. Normally, a tachycardia is followed by reflex bradycardia. The 30:15
ratio is normally > 1.03.
Heart rate response to Valsalva maneuver∗
The subject forcibly exhales into the mouthpiece of a manometer to 40 mm Hg for 15 s during ECG monitoring. Healthy subjects develop tachycardia and peripheral
vasoconstriction during strain and an overshoot bradycardia and rise in blood pressure with release. The ratio of longest to shortest R–R interval should be > 1.2.
Systolic blood pressure response to standing
Systolic blood pressure is measured in the supine subject. The patient stands and the systolic blood pressure is measure after 2 min. Normal response is a fall
of < 10 mm Hg, borderline is a fall of 10–29 mm Hg, and abnormal is a fall of > 30 mm Hg with symptoms.
Diastolic blood pressure response to isometric exercise
The subject squeezes a handgrip dynamometer to establish a maximum. Grip is then squeezed at 30% maximum for 5 min. The normal response for diastolic blood
pressure is a rise of > 16 mm Hg in the other arm.
Electrocardiographic QT/QTc intervals
The QTc (corrected QT interval on ECG) should be < 440 ms.
Neurovascular flow
Non-invasive laser Doppler measures peripheral sympathetic responses to nociception.
∗These tests can be performed quickly (<15 min) in the practitioner’s office, with a central reference laboratory providing quality control and normative values, and are
now readily available in most cardiology practices. †Lowest normal value of expiration/inspiration (E/I) ratio by age is as follows: 20–24 year, 1.17; 25–29 year, 1.15;
30–34 year, 1.13; 35–39, 1.12; 40–44 year, 1.10; 45–49 year, 1.08; 50–54 year, 1.07; 55–59 year, 1.06; 60–64 year, 1.04; 65–69 year, 1.03; 70–75 year, 1.02. ECG,
electrocardiogram; HRV, heart rate variation.
The Toronto Consensus Panel, the European Society
of Cardiology, the North American Society of Pacing and
Electrophysiology, and the ADA Position Statement on
Diabetic Neuropathy recommend the following regarding
CAN assessments for clinical trials measuring a targeted
intervention or for prognostication (Task Force of the European
Society of Cardiology and the North American Society of
Pacing and Electrophysiology, 1996; Bernardi et al., 2011;
Pop-Busui et al., 2017):
• “Standardized CARTs: simple, sensitive, specific, and
reproducible tests that assess changes in the R–R interval on
electrocardiogram recordings in response to simple clinical
maneuvers (deep breathing, Valsalva, and standing);
• Indices of HRV including sdNN and rMSSD;
• Resting HR and measurement of QTc interval on ECG
recording”.
Cardiovascular autonomic reflex tests assess cardiovascular
autonomic function through time-domain HR response to
deep breathing, Valsalva maneuver and postural change,
and by measuring the consequent changes in HR and BP.
Although indirect autonomic measures, the following CARTs are
considered the gold standard in autonomic testing: HR response
to deep breathing (E:I ratio), standing (30:15 ratio) and Valsalva
maneuver, and BP response to standing. The presence of one
abnormal cardiovagal test result identifies possible or early CAN,
to be confirmed over time. At least two abnormal cardiovagal
results are required for a definite or confirmed diagnosis of
CAN. The time-domain HR tests and the BP response to
postural change have the reproducibility necessary for clinical
trials.
Time-Domain Measures of Heart Rate
Patterns
Analysis of time-domain measures under resting conditions
offers an accurate assessment of the sympathetic and
parasympathetic regulation of the heart beat (the R–R interval
on an electrocardiogram) documented at baseline conditions
and during deep breathing, Valsalva, and standing from a
sitting position maneuvers. The sdNN is an evaluation of both
sympathetic and parasympathetic activity on HRV, and the
rMSSD is a primary indicator of parasympathetic activity.
Expiratory to inspiratory ratio (E/I ratio) measures HRV during
deep breathing, which is parasympathetic predominant. Postural
30:15 ratio is evaluated at beats 15 and 30 after standing up
and is regarded as reflective of sympathetic response and
baroreflex function. Convertino (2014) demonstrated that
cardiac parasympathetic withdrawal mediated by the carotid
cardiac baroreflex is the principal trigger for tachycardia
within milliseconds of a postural change, while sympathetic
adrenergic control sustains tachycardia during extended periods
of orthostasis. The Valsalva ratio is calculated by the longest
R–R interval during the procedure to the shortest R–R interval
throughout the duration or immediately following the maneuver.
This reaction is facilitated by the interspersed activity of
parasympathetic and sympathetic nerve fibers.
Frequency-Domain Measures
Frequency-domain analysis can identify underlying periodicities
in HR patterns. Rfa (also termed HF power) is calculated as the
area under the HR spectral curve over a frequency range fixed on
the fundamental Rfa (0.15–0.4 Hz), which is defined by the peak
mode of the respiratory activity spectrum. LF is computed as the
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area under the HR spectral curve over the frequency range from
0.04 to 0.10 Hz (Fathizadeh et al., 2004; Vinik et al., 2011).
Despite its use in research for decades, the concept that LF
and HF bands fully reflect separate influences of the sympathetic
and parasympathetic branches has been recently under debate
(Heathers and Goodwin, 2017), mainly due to their simultaneous
action in the LF power (Valenza et al., 2018). Therefore, there
has been increasing interest in using non-linear analyses of
HRV, as these may be clinically more relevant by providing a
better interpretation of the pathophysiological behavior of HRV
under various conditions and by enhancing its prognostic value
(de Godoy, 2016). Non-linear analysis methods do not assess
the magnitude of variability but rather the quality, scaling, and
correlation properties of the signals; these analyses allow a more
subtle characterization of autonomic balance and have been
shown to be more reliable markers of morbidity and mortality
in patients with CVD. A number of studies have shown that
abnormal non-linear HRV indices are associated with diabetes or
an elevated risk of developing diabetes (Roy and Ghatak, 2013;
Silva-E-Oliveira et al., 2017); and that non-linear HRV indices
in diabetic populations may have diagnostic and prognostic
potential for identifying asymptomatic CAN and cardiovascular
events (Khandoker et al., 2009; de Godoy, 2016). The technical
complexity of these analyses, however, has made interpretation
and understanding of variability challenging for common clinical
use. Further research is needed to demonstrate conclusively that
these refinements in the analysis enhance the sensitivity for
prediction of cardiovascular events (Sassi et al., 2015).
Sudorimetry Measures
Sudomotor nerves are thin unmyelinated C-fibers, with
largely cholinergic neurotransmission, where the ganglion
neurotransmitter is acetylcholine, the primary parasympathetic
nervous system neurotransmitter. However, epinephrine,
norepinephrine, vasoactive intestinal peptide (VIP), atrial
natriuretic peptide, calcitonin gene related polypeptide
(CGRP), galanin, ATP, and substance P have been identified
in periglandular nerves and thus may be contributing to
the electrical response. The addition of sudomotor function
assessments, combined with CART, may present a more precise
and well-defined early diagnosis of ANS dysfunction.
Although quantitation of intraepidermal nerve fiber density
on skin biopsies remains the gold standard and is the most
recognized technique to diagnose small nerve fiber dysfunction,
sudorimetry has the ability to produce diagnostic information
on the evaluation of the small somatosensory nerves, detection
and progression of disease, and responsiveness to therapeutic
intervention. Sudorimetry technology has advanced rapidly as
a non-invasive and precise tool to assess small fibers that can
potentially be incorporated into clinical practice.
Current sudorimetry assessments can be performed using
SudoscanTM, which measures electrochemical skin conductance
(ESC) of hands and feet. This technology is founded on
the electrochemical theories of reverse iontophoresis and
chronoamperometry to measure sudomotor function, which
makes it an affordable, practical, and precise tool generating
accurate profiles for routine clinical use and a viable research tool
on the integrity of this complex system of control. This testing has
assumed greater significance now that there are medications that
can prevent the development or progression of ANS dysfunction.
The American Association of Clinical Endocrinologists (AACE)
endorses the use of current procedural technology (CPT) code
95923 for simplified sudomotor testing and the code 95943
for evaluation of cardiac autonomic function testing. AACE
would urge that sudomotor function testing be authorized for
all practitioners seeing patients with diabetes, including primary
care, endocrinology, and podiatry. It is a non-invasive objective
test, takes a mere 2 min, and it has been compared with other
reference tests [including HRV indices, intraepidermal nerve
fiber density, and quantitative sudomotor axon reflex testing
(QSART)] and been demonstrated to be useful in the detection
of small nerve fiber neuropathy in those with and without T2DM
with a sensitivity of 77 to 87% and a specificity of 67 to 92% (AUC
0.77 to 0.88) (Casellini et al., 2013; Smith et al., 2014; Freedman
et al., 2015; Selvarajah et al., 2015; Vinik et al., 2015, 2016).
MEDICAL TREATMENT OF CARDIAC
AUTONOMIC NEUROPATHY
Cardiac autonomic neuropathy therapies are typically focused
on mitigating symptoms and should be directed to specified
clinical manifestations. Exercise, volume repletion, low dose
fludrocortisone and midodrine are among the most frequently
used therapies. Recommendations for the treatment of CAN
include the following (Pop-Busui et al., 2017):
• Early optimization of blood glucose regulation to avoid or
delay the development of CAN in people with T1DM;
• Multifaceted approach to treat hyperglycemia and
additional risk factors (e.g., dyslipidemia, hypertension) to
prevent CAN in T2DM;
• Lifestyle modifications to improve CAN in patients with
prediabetes.
Most recently there has been great interest in the action
and effects of the sodium-glucose cotransporter-2 (SGLT2)
inhibitors on reducing cardiovascular events. Empaglifozin is a
highly selective inhibitor of the SGLT2 in the kidney. Glucose
reduction occurs by decreasing renal glucose reabsorption and
thereby increasing urinary glucose elimination in patients with
diabetes, leading to significant reductions in glycated hemoglobin
(HbA1c), weight loss, and reductions in BP without increases in
HR (Liakos et al., 2014).
The EMPA-REG Outcome trial recruited 1,000 patients
with T2DM, 700 of whom were enrolled and randomized to
placebo or one of two different doses of empagliflozin (10
and 25 mg) daily in addition to standard care (Zinman et al.,
2015). Empagliflozin was similar to other oral antihyperglycemic
agents in HbA1c reduction (0.6–1%) and decreased both
fasting and postprandial glucose, with a modest weight loss
of ∼3 kg at 26 weeks vs. placebo, slightly greater weight
loss at 52 weeks, modest BP reduction of 2–7 mmHg vs.
placebo, and no intrinsic increased risk of hypoglycemia (Kishi,
2012). The initial report demonstrated a significant reduction in
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cardiovascular events (predominantly mortality and admission
to hospital for heart failure) by 35% which fast tracked the
drug to be approved for both diabetes and CVD. A subsequent
report showed that the reduction in cardiovascular deaths
were significant in Southeast Asia and Latin America, but
not as much in America and Europe (Alzaid, 2017). Despite
these different findings, the fall in BP without an increase
in HR implies a reduction in sympathetic tone with its
use.
Liraglutide, a GLP-1 receptor agonist, was also found to
reduce CV events, but not as robustly as empagliflozin (Vinik
et al., 2015). GLP-1 has widespread properties in the human
body and targets receptors diffusely (Drucker, 2016). Liraglutide
improves HbA1c and compared with other medication classes
has similar or greater efficacy, even compared to basal insulin.
Its use has been shown to lead to a modest improvement in BP
but, in contrast to empagliflozin, with an increase in HR (Scirica
et al., 2013; White et al., 2013; Green et al., 2015). The FDA
recently approved the use of liraglutide for management of CVD
in diabetes (Marso et al., 2016; Kumarathurai et al., 2017). The
actions of liraglutide on HRV and daily variation of HR in newly
diagnosed, overweight patients with T2DM and stable CAD have
been investigated. Diurnal HR fluctuations and sympathovagal
balance evaluated by rMSSD in NN intervals and HF and
LF power were assessed. Liraglutide decreased sdNN in some
subjects; decreased rMSSD; and increased mean, daytime, and
nighttime HR compared to placebo. Liraglutide reduced HF
power without any change in LF/HF ratio. Thus, in overweight
patients with CAD and newly diagnosed T2DM, liraglutide
increased HR and reduced HRV despite significant weight
loss and improvement in metabolic parameters; the increase
in nightly HR and decrease in parameters of parasympathetic
activity (rMSSD and HF power) suggest that this medication
may negatively affect sympathovagal balance (Kumarathurai
et al., 2016). The authors hypothesize that the chronotropic
effect of liraglutide, which may be mediated through the GLP-
1 receptor on the sinoatrial node, cannot explain the worsening
of HRV measures; instead, the impaired HRV may be due to a
direct influence on sympathovagal balance, as reflected by the
increase in night-time HR in conjunction with the significant
decrease in sdNN and rMSSD suggesting an impairment of
parasympathetic activity. The addition of a cholinergic agent to
a GLP-1 analog might recapture the loss of cholinergic activity
induced by a GLP-1 analog. This might even be a useful strategy
to further enhance the cardiac protection afforded by the SGLT-2
inhibitors.
NON-MEDICAL TREATMENT OF
CARDIAC AUTONOMIC NEUROPATHY
A number of researchers have demonstrated that autonomic
balance can be restored using simple lifestyle interventions,
potentially reversing CAN. Motooka et al. (2006) showed that
elderly women experienced improved HRV while walking a
dog by enhancing parasympathetic function. Removing the dog
resulted in reversal of this benefit with sympathetic overactivity
(Motooka et al., 2006). There is strong evidence indicating that
individuals with greater aerobic capacity exhibit enhanced HRV
(Tulppo et al., 2003; Luque-Casado et al., 2013). Furthermore
several studies have shown significant improvements in HRV
measures after different training programs including cycling,
walking, jogging and water aerobic exercise training in
subjects with CAD (Laing et al., 2011), inspiratory muscle
training in elderly individuals (Rodrigues et al., 2018), and
high-intensity interval training in young, healthy individuals
(de Sousa et al., 2018).
We have documented that falls and fractures in older diabetics
were often the result of loss of organized variability, strength,
and reaction times. Very simple strength and balance training
can significantly reduce falls risk (Morrison et al., 2010). For
patients with orthostatic hypotension, volume repletion with
both fluids and salt is central to management, but physical
activity and exercise are essential to prevent deconditioning,
which is known to exacerbate orthostatic intolerance (Pop-
Busui et al., 2017). The relationship between HRV and different
psychiatric disorders, as well as stress and trauma, has also
been extensively studied (Thayer et al., 2012). Subjects with
depression and anxiety disorders exhibit abnormal HRV patterns
compared with non-psychiatric controls (Servant et al., 2009).
Reduced HRV characterizes emotional dysregulation, decreased
psychological flexibility and defective social engagement, which
in turn are linked to prefrontal cortex hypoactivity (Sgoifo
et al., 2015). High occupational stress has also been associated
with lowered HRV, specifically with reduced parasympathetic
activation. There is limited evidence that use of biofeedback with
relaxation and meditation approaches may result in increased
HRV and parasympathetic activity (Servant et al., 2009). A more
detailed review on this topic is beyond the scope of this
article and the reader can refer to recent reviews on the
subject.
PREVENTION AND REVERSIBILITY OF
CARDIAC AUTONOMIC NEUROPATHY
Prevention of CAN should be a primary focus of lifestyle
and other clinical interventions. Intense glycemic control (The
Diabetes Control and Complications Trial Research Group, 1995)
utilizing a step-by-step progressive lowering of hyperglycemia,
lipids, and BP, in addition to the use of antioxidants (Ziegler
and Gries, 1997) and ACE inhibitors (Athyros et al., 1998),
reduces the odds ratio for CAN (Gaede et al., 1999, 2008).
In the EDIC study, patients with T1DM showed continuously
favorable effects of past glucose control on microvascular
complications in spite of the loss of glycemic separation
(Diabetes Control and Complications Trial Research Group,
1993; Writing Team for the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Complications
Research Group, 2003). CAN progressed in both treatment
groups during the EDIC follow-up, but the prevalence and
incidence continued to be decreased in the previous intensive
group compared to the standard group despite comparable
levels of glycemic control. To diminish the development of
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CAN, intense glucose control of T1DM ought to be started
as soon as possible (Pop-Busui et al., 2009). However, in
patients with established CAN, glycemic control may need to
be less stringent to avoid hypoglycemia and adverse drug effects
(Inzucchi et al., 2015). The American Diabetes Association
also recommends that individuals with CAN have a cardiac
evaluation before starting or increasing physical activity for safety
reasons (American Diabetes Association, 2017; Pop-Busui et al.,
2017).
Pathogenesis-oriented interventions may promote some
degree of reversal of established CAN (Vinik et al., 2011). Lifestyle
interventions, increased physical activity, β-adrenergic blockers,
aldose reductase inhibitors, ACE inhibitors, ARBs, and potent
antioxidants such as α-lipoic acid have all been shown to restore
autonomic balance. Enhanced glycemic control with a reduced
HbA1c from 9.5 to 8.4 improved HRV in patients with T1DM
with minimal autonomic abnormalities, but not in those with
advanced autonomic irregularities (Burger et al., 1999). The
Veterans Administration Cooperative Study showed no impact
on the occurrence of CAN after 2 years of intense glycemic
control in patients with T2DM (Azad et al., 1999); however,
people with T2DM receiving rigorous multifactorial therapies
that targeted hypertension, hyperglycemia, dyslipidemia, and
microalbuminuria, along with secondary CVD preventative
measures like aspirin use, experienced a 63% reduction in
ANS dysfunction in the Steno-2 Study. Although glucose-
lowering agents exerted the least benefit in comparison with
antihypertensive treatments, lipid-lowering agents, aspirin, and
vitamin-mineral supplements (Gaede et al., 1999), this favorable
effect continued after ∼13 years of follow-up (Gaede et al.,
FIGURE 1 | Schematic of dopamine – clock interactions in the regulation of fuel metabolism. Figure illustrates the hypothalamic clock with decreased suprachiasmic
nuclear (SCN) early morning peak of dopamine activity and enhanced activity of the paraventricular nucleus (PVN), which increase autonomic tone and the
paraventricular nucleus to raise levels of corticotrophin releasing hormone (CRH). The consequences include activation of the sympathetic nervous system (SNS)
hypothalamic and glucose sensitization reducing parasympathetic (vagal drive) to the liver and resistance to both leptin and insulin. CRH, corticotrophin releasing
hormone; eNOS, endothelial nitric oxide synthase; FFAs, free fatty acids; NPY, neuropeptide Y; PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus; SNS,
sympathetic nervous system; TGs, triglycerides; VMH, ventromedial hypothalamus (Raskin and Cincotta, 2016).
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2008). Early identification of CAN also may allow for the
well-timed initiation of antioxidant alpha-lipoic acid therapies
that slow or reverse advancement of CAN (Ziegler and Gries,
1997).
Certain medications hold promise for the prevention and
reversal of CAN. Early therapeutic intervention with ACE
inhibition or ARBs improved both CAN and left ventricular
diastolic dysfunction after 1 year of treatment in patients
with no symptoms and long-term diabetes. The combined
therapies were slightly superior to monotherapies, auguring
well for patients with established CAN (Didangelos et al.,
2006). Treatment with fluvastatin improves cardiac sympathetic
neuropathy in the diabetic rat heart in relation to attenuation
of increased cardiac oxidative stress (Matsuki et al., 2010).
Alternatively, selective inactivation of cyclooxygenase-2 (COX-
2) guards against sympathetic denervation in experimental
diabetes by decreasing intramyocardial oxidative stress and
inflammation (Kellogg et al., 2009). Consequently, statins
and COX-2 inactivation may assist in attenuating cardiac
sympathetic dysfunction. In addition, it has been shown that
early mortality is a consequence of beat-to-beat variability
loss with MI, but can be reduced by 33% with the immediate
administration of insulin (Malmberg et al., 1999). Successful
pancreas transplantation showed improvements in epinephrine
response and normalized hypoglycemia symptom awareness in
patients with established diabetes (Burger et al., 1999) as well as
evidence of a reversible metabolic component in patients with
early CAN (Kendall et al., 1997).
Weight loss and weight-reducing surgeries may also
potentially reduce CAN. ANS dysfunction and increased
sympathetic activity have been directly correlated with obesity
(Piestrzeniewicz et al., 2008; Straznicky et al., 2009; Lambert
E. et al., 2010; Lambert G. W. et al., 2010). Moreover, weight
reduction significantly improves HRV and reduces ANS
imbalances (Karason et al., 1999; Maser et al., 2007; Nault
et al., 2007; Perugini et al., 2010; Ravussin, 2010; Casellini
et al., 2015, 2016; Ziegler et al., 2015a). To evaluate the ability
to reverse autonomic imbalance, we examined sudomotor
function and HRV measurements in obese patients undergoing
bariatric surgery. Patients were assessed at baseline, 4, 12,
and 24 weeks after vertical sleeve gastrectomy or Roux-en-Y
gastric bypass. Seventy subjects completed at least 24-weeks
of follow-up. Sudorimetry results of ESC of feet improved
significantly trending toward normal in T2DM patients.
HRV improved significantly, as did many other metabolic
parameters. Improvements in feet ESC were shown to be
independently associated with HbA1c, insulin, and HOMA2-IR
levels at baseline, as well as HbA1c at 24 weeks. Additionally,
improvement in basal HR had an independent association
with HbA1C, insulin and HOMA2-IR levels. These positive
results suggest that bariatric surgery can return both cardiac
and sudomotor autonomic C-fiber dysfunction in those with
diabetes to normal, possibly positively influencing morbidity and
mortality (Casellini et al., 2016).
FUTURE DIRECTIONS OF RESEARCH
TO PREVENT AND REVERSE CARDIAC
AUTONOMIC NEUROPATHY
The host of targets that are potential candidates for reduction
of cardiovascular risk have been addressed in the previous
paragraphs. For years we were confronted with glycemic control
as the only measure by the glucocentric majority and those
who believed in the lipid hypothesis who have now carried
this to the extreme of need for even lower LDL-C in high risk
patients. The entry of SGLT2 inhibitors and the incretins shed
new light on the challenge armed with new ammunition and
also created an avenue of adventure for those interested in novel
pathways. However the initial inroad into reduction of CV events
was a discovery of the power of resetting a biologic clock and
targeting the brain rather than other members of the dreadful
dektet!
It has been established that there is a brain dopamine
deficiency in obese diabetic patients present in the early hours
of the morning (Cincotta et al., 1999). The working hypothesis
is that in early morning, decreased dopaminergic tone in
the hypothalamus unbridles sympathetic activation with all its
TABLE 2 | Impact of bromocriptine-QR on CV death-inclusive composite cardiovascular endpoint and individual components of the composite as well as the MACE
endpoint.
Bromocriptine-QR
(N = 2054), n (%)∗
Placebo
(N = 1016) n (%)∗
Hazard ratio
(95% CI)
CV death-inclusive composite cardiovascular endpoint 39 (1.9) 33 (3.2) 0.61 (0.38 TO 0.97)
Myocardial infarction 7 (0.3) 9 (0.9) 0.41 (0.15 to 1.11)
Stroke 5 (0.2) 6 (0.6) 0.44 (0.13 to 1.43)
Hospitalization for angina 9 (0.4) 9 (0.9) 0.52 (0.21 to 1.30)
Hospitalization for heart failure 9 (0.4) 6 (0.6) 0.77 (0.27 to 2.16)
Coronary revascularization 11 (0.5) 8 (0.8) 0.72 (0.29 to 1.80)
CV death 4 (0.2) 2 (0.2) 0.48 (0.07 to 3.43)
Coronary revascularization following a primary endpoint (i.e., CABG after MI) 9 (0.4) 11 (1.1) 0.43 (0.18 to 1.03)
MACE composite-myocardial infarction, stroke, CV death 14 (0.7) 15 (1.5) 0.48 (0.23 to 1.00)
∗Percentage of events per total number per group; 2054 bromocriptine-QR, 1016 placebo. CI, confidence interval; CV, cardiovascular; CABG, coronary artery bypass
graft; MACE, major cardiovascular adverse event; MI, myocardial infarction (Gaziano et al., 2012).
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consequences, as illustrated in Figure 1. Restoring the morning
peak in dopaminergic activity by dopamine D2 receptor-
mediated activities may, therefore, restore ANS balance.
It may also be possible to reset the biologic hypothalamic
clock and ANS function using bromocriptine QR to restore
morning dopaminergic activity. It sensitizes the body to insulin
and reduces sympathetic tone thereby reducing HR (Raskin and
Cincotta, 2016). Bromocriptine QR has also demonstrated a
favorable effect on CV outcomes in clinical trials (Figure 1 and
Table 2) (Gaziano et al., 2012), suggesting a future direction
for pathogenesis-oriented therapies (Vinik et al., 2011). Our
current quest is to determine if any of the novel discoveries
in cardiovascular outcome studies (CVOTs) are indeed working
through rebalancing the ANS thereby creating a wonderful
opportunity for taking a fork in the road.
CONCLUSION
An improvement in ANS balance may be critical to reducing
cardiovascular events and early mortality. Symptoms and signs
of autonomic dysfunction, including resting HR, BP responses to
standing, and time and frequency measures of HRV in response
to deep breathing, standing and Valsalva maneuver, should be
elicited from all patients with diabetes to allow for early detection
and intervention. With the recognition of the presence of ANS
imbalance or for its prevention, a rigorous regime should be
implemented with lifestyle modification, physical activity, and
cautious use of medications that lower blood glucose. Rather
than intensifying diabetes blood glucose management, a regimen
tailored to the individual risk of ANS dysfunction should be
constructed. The advent of new agents that may have the potential
to improve ANS function, such as the SGLT2 inhibitors and
the GLP-1 agonists, should be considered. However, it is not
clear how these compounds work and what the mechanism
of reduction of major adverse cardiovascular events is. An
overlooked mechanism is a resetting of the biologic clock with
correction of the dopamine deficiencies in the brainstem of obese
people with diabetes, restoring the functioning of the ANS with
its potential for significant reduction of cardiovascular events.
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